Literature DB >> 10843458

Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

N M Davies1, N M Skjodt.   

Abstract

Effective use of the growing number of nonsteroidal anti-inflammatory drugs (NSAIDs), a group that has recently been augmented by the introduction of the selective cyclo-oxygenase-2 inhibitors, requires adequate knowledge of their pharmacokinetics. After oral administration, the absorption of NSAIDs is generally rapid and complete. NSAIDs are highly bound to plasma proteins, specifically to albumin (>90%). The volume of distribution of NSAIDs is low, ranging from 0.1 to 0.3 L/kg, suggesting minimal tissue binding. NSAID binding in plasma can be saturated when the concentration of the NSAID exceeds that of albumin. Most NSAIDs are metabolised by the liver, with subsequent excretion into urine or bile. Enterohepatic recirculation occurs when a significant amount of an NSAID or its conjugated metabolites are excreted into the bile and then reabsorbed in the distal intestine. NSAID elimination is not dependent on hepatic blood flow. Hepatic NSAID elimination is dependent on the free fraction of NSAID within the plasma and the intrinsic enzyme activities of the liver. Renal elimination is not an important elimination pathway for NSAIDs, except for azapropazone. The plasma half-life of NSAIDs ranges from 0.25 to >70 hours, indicating wide differences in clearance rates. Hepatic or renal disease can alter NSAID protein binding and metabolism. Some NSAIDs with elimination predominantly via acylglucuronidation can have significantly altered disposition. Pharmacokinetics are also influenced by chronobiology, and many NSAIDs exhibit stereoselectivity. There appear to be relationships between NSAID concentration and effects. At therapeutically equivalent doses, NSAIDs appear to be equally efficacious. The major differences between NSAIDs are their therapeutic half-lives and safety profiles. NSAIDs undergo drug interactions through protein binding displacement and competition for active renal tubular secretion with other organic acids. When choosing the right NSAID for the right patient, individual patient-specific and NSAID-specific pharmacokinetic principles should be considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843458     DOI: 10.2165/00003088-200038050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  81 in total

1.  Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion.

Authors:  F Jamali; R Mehvar; A S Russell; S Sattari; W W Yakimets; J Koo
Journal:  J Pharm Sci       Date:  1992-03       Impact factor: 3.534

Review 2.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 3.  Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs.

Authors:  R K Verbeeck
Journal:  J Rheumatol Suppl       Date:  1988-10

4.  Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability.

Authors:  N M Davies; M R Wright; A S Russell; F Jamali
Journal:  J Pharm Sci       Date:  1996-11       Impact factor: 3.534

5.  Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis.

Authors:  J D Bradley; A C Rudy; B P Katz; S I Ryan; L A Kalasinski; D C Brater; S D Hall; K D Brandt
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 6.  Clinical pharmacology of NSAIDs.

Authors:  D C Brater
Journal:  J Clin Pharmacol       Date:  1988-06       Impact factor: 3.126

Review 7.  The propionic acids: a personal perspective.

Authors:  S S Adams
Journal:  J Clin Pharmacol       Date:  1992-04       Impact factor: 3.126

8.  Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders.

Authors:  N Baber; L D Halliday; W J van den Heuvel; R W Walker; R Sibeon; J P Keenan; T Littler; M L Orme
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

9.  Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.

Authors:  R O Day; H Francis; J Vial; G Geisslinger; K M Williams
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

10.  Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.

Authors:  P Bertin; F Lapicque; E Payan; M Rigaud; F Bailleul; S Jaeger; R Treves; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more
  15 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat.

Authors:  Alexandra Wibberley; Gerald P McCafferty; Christopher Evans; Richard M Edwards; J Paul Hieble
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

3.  MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression.

Authors:  Nicolas M Zahn; Alec T Huber; Brandon N Mikulsky; Mae E Stepanski; Alexander S Kehoe; Guanguan Li; Melissa Schussman; Mohammed S Rashid Roni; Revathi Kodali; James M Cook; Douglas C Stafford; Douglas A Steeber; Leggy A Arnold
Journal:  Basic Clin Pharmacol Toxicol       Date:  2019-02-21       Impact factor: 4.080

4.  Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin.

Authors:  Jagan Mohan R Parepally; Haritha Mandula; Quentin R Smith
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

5.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

Authors:  Bengt Hamrén; Hans Ericsson; Ola Samuelsson; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

Review 6.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

7.  Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs.

Authors:  Daniel E Westholm; David D Stenehjem; Jon N Rumbley; Lester R Drewes; Grant W Anderson
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

Review 8.  Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.

Authors:  Jody K Takemoto; Jonathan K Reynolds; Connie M Remsberg; Karina R Vega-Villa; Neal M Davies
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.

Authors:  Maria Cekanova; Md Jashim Uddin; Alfred M Legendre; Gina Galyon; Joseph W Bartges; Amanda Callens; Tomas Martin-Jimenez; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

Review 10.  Nonsteroidal anti-inflammatory drugs and heart failure.

Authors:  Gysèle S Bleumink; Johannes Feenstra; Miriam C J M Sturkenboom; Bruno H Ch Stricker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.